Drug intelligence / Profile preview

MSP103

Development stage: Preclinical
Lead developer: Methapharm
Modality: Small Molecules
Administration: Inhalation

Overview

MSP103 is a respiratory drug candidate currently in development by Methapharm. It is part of the company's specialty respiratory portfolio, which focuses on diagnostic and therapeutic products for lung health, such as bronchoprovocation challenge agents. As of the 2024 pipeline update, the specific active pharmaceutical ingredient and molecular target for MSP103 have not been publicly disclosed. However, the product is scheduled for a target launch in 2024, suggesting it is in the late stages of clinical development or undergoing regulatory review.

Beyond the preview

Go deeper on MSP103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSP103.

Explore the full profile